Physician profile
Cole Crowson
NPI 1942799531
$12,550.03
in general payments reported to CMS, 2019-2025
20 companies · $12K in 2025
The $12K reported for 2025 was more than what 90% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,032 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,250 · Food and Beverage: $4,281 · Travel and Lodging: $811 · Education: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,250.00 |
| Food and Beverage | $4,281.34 |
| Travel and Lodging | $810.80 |
| Education | $207.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $8,534.06 | 2025 | Ocrevus, Ocrevus Zunovo |
| Tg Therapeutics, INC. | $1,307.67 | 2024-2025 | |
| Abbvie INC. | $577.98 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $458.44 | 2024-2025 | Ultomiris |
| Genentech, INC. | $335.76 | 2024-2025 | Ocrevus, Ocrevus Zunovo |
| Emd Serono, INC. | $300.37 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $224.09 | 2025 | |
| Biogen, INC. | $188.83 | 2024-2025 | Tysabri, Vumerity |
| Celgene Corporation | $186.68 | 2024-2025 | Zeposia |
| Pfizer INC. | $147.69 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $55.27 | 2025 | Austedo Xr, Ajovy |
| Vanda Pharmaceuticals INC. | $54.78 | 2024-2025 | Ponvory |
| Ucb, INC. | $33.64 | 2024-2025 | Fintepla, Briviact |
| Catalyst Pharmaceuticals, INC. | $27.45 | 2025 | |
| Janssen Biotech, INC. | $24.83 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $23.79 | 2025 | Uplizna |
| Microtransponder, INC. | $22.96 | 2025 | |
| Springworks Therapeutics, INC. | $15.76 | 2025 | Gomekli |
| Globus Medical, INC. | $15.40 | 2025 | Senza |
| Jazz Pharmaceuticals INC. | $14.58 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cole Crowson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.